Atai Life Sciences Announces Results From The Phase 1 IV-To-Subcutaneous Bridging Study Of PCN-101 (R-Ketamine)
Portfolio Pulse from Benzinga Newsdesk
Atai Life Sciences (NASDAQ: ATAI) announced results from Perception Neuroscience's Phase 1 study of PCN-101 (R-ketamine). The study assessed the safety, tolerability, and pharmacokinetic profile of different doses of PCN-101 delivered subcutaneously compared to intravenously. The results indicate that 120mg of PCN-101 delivered subcutaneously resulted in an approximate doubling of drug exposure while maintaining the same maximum concentration as the 60mg IV dose. The drug was generally well-tolerated with no serious adverse events reported.
August 08, 2023 | 9:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atai Life Sciences announced positive results from a Phase 1 study of PCN-101, which could potentially lead to increased investor confidence and a positive impact on the company's stock.
Positive clinical trial results often lead to increased investor confidence, which can positively impact a company's stock price. Given that the results indicate that PCN-101 was well-tolerated and showed increased drug exposure, this could potentially lead to increased investor interest in Atai Life Sciences.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100